Predictive Oncology Top Insiders
| POAIDelisted Stock | USD 5.95 0.00 0.00% |
Predictive Oncology employs about 23 people. The company is managed by 12 executives with a total tenure of roughly 54 years, averaging almost 4.0 years of service per executive, having 1.92 employees per reported executive. Assessment of Predictive Oncology's management performance can provide insight into the firm performance.
Predictive |
Predictive Oncology Management Team Effectiveness
The company has return on total asset (ROA) of (1.288) % which means that it has lost $1.288 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.4603) %, meaning that it created substantial loss on money invested by shareholders. Predictive Oncology's management efficiency ratios could be used to measure how well Predictive Oncology manages its routine affairs as well as how well it operates its assets and liabilities.The market capitalization of Predictive Oncology is $20.09 Million. Predictive Oncology holds 4.92 pct. of its outstanding shares held by insiders and 0.15 pct. owned by third-party entities. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Some institutional investors establish a significant position in stocks such as Predictive Oncology in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Predictive Oncology, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Predictive Oncology Workforce Comparison
Predictive Oncology is regarded third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 215. Predictive Oncology retains roughly 23.0 in number of employees claiming about 11% of equities under Health Care industry.
Predictive Oncology Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Predictive Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Predictive Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Predictive Oncology insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Raymond Vennare over a month ago Disposition of 2373 shares by Raymond Vennare of Predictive Oncology at 5.9 subject to Rule 16b-3 | ||
Matthews Shawn over three months ago Insider Trading | ||
Smith David Stewart over three months ago Acquisition by Smith David Stewart of 18911 shares of Predictive Oncology subject to Rule 16b-3 | ||
Raymond Vennare over three months ago Acquisition by Raymond Vennare of 124959 shares of Predictive Oncology subject to Rule 16b-3 | ||
St. Clair Gregory Sr over six months ago Acquisition by St. Clair Gregory Sr of 6265 shares of Predictive Oncology subject to Rule 16b-3 | ||
Raymond Vennare over six months ago Acquisition by Raymond Vennare of 4600 shares of Predictive Oncology at 0.5164 subject to Rule 16b-3 | ||
Handley Daniel E over six months ago Acquisition by Handley Daniel E of 2800 shares of Predictive Oncology at 0.35 subject to Rule 16b-3 | ||
Nuzum Charles Lee Sr over a year ago Acquisition by Nuzum Charles Lee Sr of 6265 shares of Predictive Oncology subject to Rule 16b-3 |
Predictive Oncology Notable Stakeholders
A Predictive Oncology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Predictive Oncology often face trade-offs trying to please all of them. Predictive Oncology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Predictive Oncology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| MD FCAP | Senior Director | Profile | |
| Joshua MBA | Interim Officer | Profile | |
| BS BSc | VP RD | Profile | |
| Pamela MBA | Chief Officer | Profile | |
| Thomas McLaughlin | Chief Officer | Profile | |
| Sara JD | Senior Counsel | Profile | |
| Raymond Vennare | CEO Chairman | Profile | |
| DSc OD | VP Operations | Profile | |
| Julia Kirshner | Chief Officer | Profile | |
| Robert Myers | CFO Sec | Profile | |
| Robert MBA | CFO Sec | Profile | |
| Theresa Ferguson | Director Marketing | Profile |
About Predictive Oncology Management Performance
The success or failure of an entity such as Predictive Oncology often depends on how effective the management is. Predictive Oncology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Predictive management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Predictive management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence primarily in the United States. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota. Predictive Oncology operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 30 people.
Predictive Oncology Workforce Analysis
Traditionally, organizations such as Predictive Oncology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Predictive Oncology within its industry.Predictive Oncology Manpower Efficiency
Return on Predictive Oncology Manpower
| Revenue Per Employee | 70.6K | |
| Revenue Per Executive | 135.3K | |
| Net Loss Per Employee | 472.2K | |
| Net Loss Per Executive | 905K |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Predictive Stock
If you are still planning to invest in Predictive Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Predictive Oncology's history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |